首页> 外文期刊>Psychopharmacology >Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug na?ve, first-episode schizophrenia
【24h】

Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug na?ve, first-episode schizophrenia

机译:初治精神分裂症初次精神分裂症患者进行6个月利培酮治疗期间促炎细胞因子和体重的变化

获取原文
获取原文并翻译 | 示例
       

摘要

Objective: The present study aimed to examine the changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug na?ve, first-episode schizophrenia. Methods: Sixty-two drug na?ve, first-episode schizophrenia (SZ group) and 60 healthy individuals (control group) were enrolled in the study. Serum interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) levels, and body weight were measured at baseline for both groups, and repeated for the SZ group at five different time points during 6-month risperidone treatment. Results: At baseline, serum IL-1β, IL-6, and TNF-α levels in the SZ group (53.28 ± 12.62, 33.98 ± 14.13, 50.08 ± 12.86 pg/mL, respectively) were significantly higher than those in the control group (23.49 ± 15.27, 15.53 ± 7.16, 32.12 ± 15.23 pg/mL, respectively) (p's < 0.001). Within the SZ group, serum IL-1β levels decreased significantly at 2 weeks (48.02 ± 16.00 pg/mL, p < 0.01) and 1 month (44.70 ± 16.63 pg/mL, p < 0.001), but then gradually increased at 2 months (48.49 ± 18.87 pg/mL), 3 months (50.59 ± 18.48 pg/mL) and 6 months (53.64 ± 16.22 pg/mL) to the levels comparable to baseline; serum IL-6 levels changed significantly over the course of treatment (p = 0.001), but reached the levels comparable to baseline at 6 months (37.13 ± 13.23 pg/mL); serum levels of TNF-α increased significantly at 3 months (55.02 ± 16.69 pg/mL, p < 0.01) and 6 months (58.69 ± 13.57 pg/mL, p < 0.001); steady and significant weight gain was observed at each follow-up time point (p's < 0.001), from 56.71 ± 9.25 kg at baseline to 62.72 ± 9.53 kg at 6 months. Conclusions: Risperidone treatment is associated with changes in serum pro-inflammatory cytokines levels and weight. There is an initial anti-inflammatory effect that reduces with treatment, potentially due to its weight gain side effect.
机译:目的:本研究旨在探讨初治,首发性精神分裂症患者在6个月利培酮治疗过程中促炎细胞因子和体重的变化。方法:纳入62例初治精神分裂症,初发性精神分裂症(SZ组)和60例健康个体(对照组)。两组均在基线时测量血清白细胞介素-1β(IL-1β),白细胞介素-6(IL-6),肿瘤坏死因子-α(TNF-α)水平和体重,SZ组在第5次重复利培酮治疗6个月期间的时间不同。结果:在基线时,SZ组的血清IL-1β,IL-6和TNF-α水平(分别为53.28±12.62、33.98±14.13、50.08±12.86 pg / mL)显着高于对照组。 (分别为23.49±15.27、15.53±7.16、32.12±15.23 pg / mL)(p's <0.001)。在SZ组内,血清IL-1β水平在2周(48.02±16.00 pg / mL,p <0.01)和1个月(44.70±16.63 pg / mL,p <0.001)显着下降,但在2个月后逐渐升高(48.49±18.87 pg / mL),3个月(50.59±18.48 pg / mL)和6个月(53.64±16.22 pg / mL)至与基线相当的水平;血清IL-6水平在治疗过程中发生了显着变化(p = 0.001),但在6个月时达到了与基线相当的水平(37.13±13.23 pg / mL);血清TNF-α水平在3个月(55.02±16.69 pg / mL,p <0.01)和6个月(58.69±13.57 pg / mL,p <0.001)显着增加;在每个随访时间点均观察到稳定且显着的体重增加(p's 0.001),从基线时的56.71±9.25 kg增加到6个月时的62.72±9.53 kg。结论:利培酮治疗与血清促炎细胞因子水平和体重的变化有关。最初的抗炎作用会随着治疗而降低,这可能是由于其体重增加的副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号